FRANK-RECRUITMENT-GROUP
12.1.2021 16:02:33 CET | Business Wire | Press release
UK staffing firm Frank Recruitment Group has today announced the opening of its latest location in Geneva, Switzerland.
The new office is the cloud recruitment company's eighth in Europe, bringing its total number of global hubs to 21.
Frank Recruitment Group, founded in Newcastle upon Tyne in 2006 with just three members of staff, now employs almost 2,000 people worldwide and is part of Tenth Revolution Group, the global leader in cloud talent solutions. The Swiss location will add a number of new team members to that headcount, with plans to create up to 50 jobs within five years.
The move will see Frank Recruitment Group further increase its reach in Europe and enable the firm to better support its growing global client base.
With the country's technology market expanding fast, and digitalisation and cloud migration at the top of every Swiss CIO's agenda, demand for IT professionals to support transformation is mounting.
"Our new Swiss base will allow us to offer better support to our clients and partners in the region, at a time when specialist technology recruitment consulting is more needed than ever," said Director of Sales Paul Hanley, who will be leading the new location.
"We want to replicate the success we’ve achieved in other global regions here in Switzerland by solidifying our position as the leaders in cloud tech staffing solutions, and continue to enable digital transformation by delivering the best permanent and contract tech talent to businesses that need it," Hanley said.
"I'm especially proud to be launching our Swiss office," said Zoë Morris, Frank Recruitment Group President. "2020 was a challenging year for the staffing industry, so it feels like a special achievement to be opening a new location and growing our business at this time. We feel very privileged to be able to serve this exciting market and create new jobs in the area in the process."
Hanley added, "Our launch team is packed with seasoned, multi-lingual staffing experts, all of whom have significant experience within the Swiss recruitment industry. Our focus is entirely on the tech market, and that will allow us to deliver the kind of dedicated, specialist expertise that's been missing in the Swiss market so far. I'm incredibly excited to get to work in the market, and make a real impact for both businesses and tech professionals in the area by connecting the right people with the right jobs."
At the new location, Frank Recruitment Group will initially launch its Nigel Frank, Mason Frank, and FRG Technology Consulting brands, which recruit for Microsoft, Salesforce, and emerging technology specialists, respectively.
The Swiss office is based at 14 Rue du Rhône, Geneva.
Note to editors:
ABOUT FRANK RECRUITMENT GROUP
Frank Recruitment Group is a division of Tenth Revolution Group, the world’s leading experts in cloud talent solutions. Founded in Newcastle upon Tyne, in 2006, Frank Recruitment Group creates and delivers highly sought-after professionals in some of the industry’s most skills-scarce ecosystems.
The company employs nearly 2,000 people across 20 offices, including Dallas, New York, Philadelphia, San Francisco, Tampa, Denver, Scottsdale, Charlotte, and Irvine in the US. EMEA and APAC are served by nine offices across the UK, Germany, the Netherlands, Spain, and locations in Singapore and Australia.
The group operates seven trading brands that each focus on a specific technology product: Jefferson Frank (AWS), Nigel Frank International (Microsoft Dynamics and Azure), Mason Frank International (Salesforce), Washington Frank (enterprise ERP), Anderson Frank (NetSuite), Nelson Frank (ServiceNow), and FRG Technology Consulting (Marketing Automation and emerging technologies).
Frank Recruitment Group was named one of Europe’s fastest-growing companies and received recognition as one of the UK’s top 100 private companies with the fastest-growing profits . The group plans to expand its outreach globally and attract more trainee recruiters in strategic hubs to meet demand for its services.
For more information, visit: www.frankgroup.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005733/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom